DARA BioSciences, Inc. (NASDAQ: DARA) is an oncology supportive care pharmaceutical company dedicated to providing healthcare professionals a synergistic portfolio of medicines to help cancer patients adhere to their therapy and manage side effects arising from their cancer treatments. DARA holds the exclusive U.S. marketing rights to Soltamox, a novel oral liquid formulation of tamoxifen citrate (the only FDA-approved version of it in the U.S.), which is widely used in the treatment and prevention of breast cancer. For more information, visit the company’s website at www.darabiosciences.com.